NSCLC cells treated with PARP inhibitors (PARPi) induce the cell surface expression of the PD-L1 immune checkpoint inhibitor and secrete the CCL5 chemokine (Chabanon et al., 2019). This evidence concerns the gene PARP1 and non-small cell lung carcinoma.